Mika Salminen

Mika Salminen

Auto-generated profile, based on publicly available information

Mika Salminen

Department of Infectious Disease Epidemiology, National Public Health Institute, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1995 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
MSMika O. Salminen
Mika O. Salminen
JCJean K. Carr
Jean K. Carr
DBDonald S. Burke
Donald S. Burke
FMFRANCINE E. McCUTCHAN
FRANCINE E. McCUTCHAN

2 August 2005 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TOTulio de Oliveira
Tulio de Oliveira
KDKoen Deforche
Koen Deforche
SCSharon Cassol
Sharon Cassol
MSMika Salminen
Mika Salminen
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
DADavid A.
David A.
Motivation: Genetic analysis of HIV-1 is important not only for vaccine development, but also to guide treatment strategies, track the emergence of new viral variants and ensure that diagnostic assays are contemporary and fully optimized. However, most genotyping methods are laborious and complex, and involve the use of multiple software applications. Here, we describe the development of an automated genotyping system that can be easily applied to HIV-1 and other rapidly evolving viral pathogens. Results: The new REGA subtyping tool, developed using Java programming and PERL scripts, combines phylogenetic analyses with bootscanning methods for the genetic subtyping of full-length and subgenomic fragments of HIV-1. When used to investigate the subtype of previously published reference datasets that were analysed using manual phylogenetic methods, the automated method correctly identified 97.5–100% of non-recombinant and circulating recombinant forms of HIV-1, including 108 full-length, 108 gag and 221 env sequences downloaded from the Los Alamos database. Availability: The tool, which can be easily downloaded and installed on either a UNIX or Linux-based computer system, is available at http://www.bioafrica.net/subtypetool/html/ Contact:tulio.deoliveira@zoology.oxford.ac.uk

1 February 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JHJoris Hemelaar
Joris Hemelaar
RERamyiadarsini Elangovan
Ramyiadarsini Elangovan
JYJason Yun
Jason Yun
LDLeslie Dickson-Tetteh
Leslie Dickson-Tetteh
IFIsabella Fleminger
Isabella Fleminger
RZRong Zhang
Rong Zhang

15 September 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AWAnnemarie M. J. Wensing
Annemarie M. J. Wensing
DVDavid A. van de Vijver
David A. van de Vijver
GAGioacchino Angarano
Gioacchino Angarano
BÅBirgitta Åsjö
Birgitta Åsjö
CBClaudia Balotta
Claudia Balotta
SPSpread Programme
Spread Programme
BackgroundInfection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transm

1 January 2014 in International Journal of Drug Policy
Verified
Journal Article
Closed access
GMGeorgie MacArthur
Georgie MacArthur
EVEva van Velzen
Eva van Velzen
NPNorah Palmateer
Norah Palmateer
JKJo Kimber
Jo Kimber
APAnastasia Pharris
Anastasia Pharris
SHSharon J. Hutchinson
Sharon J. Hutchinson

19 March 2020 in Eurosurveillance
Verified
Journal Article
Open access
AHAnu Haveri
Anu Haveri
TSTeemu Smura
Teemu Smura
SKSuvi Kuivanen
Suvi Kuivanen
PÖPamela Österlund
Pamela Österlund
JHJussi Hepojoki
Jussi Hepojoki
CSCarita Savolainen-Kopra
Carita Savolainen-Kopra
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3–23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.